| Literature DB >> 18393797 |
Arun K Ghosh1, Nagaswamy Kumaragurubaran, Ling Hong, Gerald Koelsh, Jordan Tang.
Abstract
Memapsin 2 (beta-secretase, BACE 1) processing of beta-amyloid precursor protein is the first step in the pathway leading to the production of amyloid-beta, thus, it is a major target for the development of inhibitor drug for the treatment of Alzheimers's Disease. Although there are distinctive advantages of this protease as a drug target, the development of drug-like memapsin 2 inhibitors has been somewhat slow since the cloning of the protease seven years ago. Here we review the progress of memapsin 2 inhibitor development using crystal structure-based design cycles. Recent progress has evolved the inhibitors into sizes sufficiently small to penetrate cell membranes and the blood-brain barrier yet retain potency for the inhibition of Abeta production in cultured cells and experimental animals. Such progress lends optimism that clinically useful memapsin 2 inhibitors will eventually be developed.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18393797 DOI: 10.2174/156720508783954730
Source DB: PubMed Journal: Curr Alzheimer Res ISSN: 1567-2050 Impact factor: 3.498